Ironwood Pharmaceuticals Repays $200M Convertible Notes Using Cash on Hand
IRWD has more than doubled off its 52-week low of $0.612.
Summary
Ironwood Pharmaceuticals repaid $200 million in convertible senior notes using cash on hand, reducing debt and avoiding dilution.
Key Events · Financing and Capital Events · IRWD
-
$200 Million Debt Repayment
The company repaid the full $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity.
-
Funded by Cash on Hand
The repayment was funded using proceeds from available cash on hand, indicating strong liquidity.
-
No Share Dilution
No conversions were exercised by holders of the convertible notes, preventing potential dilution for existing shareholders.
-
Capped Call Transactions Terminated
The associated capped call transactions, entered into when the notes were issued, terminated upon expiry.
Analysis · IRWD · Life Sciences
Ironwood Pharmaceuticals successfully repaid its $200 million convertible senior notes at maturity using existing cash, demonstrating strong liquidity and financial stability. This significant debt reduction removes a major liability from the balance sheet and avoids potential dilution, as no conversions were exercised.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRWD was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $607.4M. The 52-week trading range was $0.61 to $5.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.